Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rovalpituzumab tesirine

- PMLiVE

Royalty Pharma raises Elan bid as deals keep coming

Values Elan at about $6.5bn

- PMLiVE

Actavis to buy Warner Chilcott in $8.5bn deal

Combined company will have annual revenues of about $11bn

Bayer symbol

Bayer boosts consumer care business with Steigerwald purchase

Fuels ambition to become world leader in OTC medicines

Payer focus in the personalised world of oncology and orphan diseases

Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding

Bayer symbol

FDA clears Bayer/ Algeta’s prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of schedule

- PMLiVE

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients

New indication approved alongside companion diagnostic to detect gene mutation

- PMLiVE

Endocyte appoints Parexel’s Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly

Pharma deals during April 2013

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

Deal Watch table for April 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

- PMLiVE

AbbVie gets ‘breakthrough’ status for hepatitis C regimen

Combination could be all-oral alternative to injectable interferon alpha-based therapies

- PMLiVE

Roche survey says Scottish cancer patients moving house to get treatment

But NHS Scotland hits back at report's "extremely dubious" findings

- PMLiVE

FDA committee turns down Aveo/Astellas’ cancer drug

Tivozanib unable to prove superiority to Bayer's Nexavar

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links